CATX Stock Forecast: Perspective Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Perspective Therapeutics, Inc. is $9.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 11 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Perspective Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (54): The business earns solid, repeatable profits on what it owns.
Value (19): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CATX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CATX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Nov 2026 | Piper Sandler | Maintains | Overweight | — |
| 10 Nov 2026 | Truist Securities | Maintains | Buy | — |
| 10 Nov 2026 | Wedbush | Maintains | Outperform | — |
| 26 Oct 2026 | RBC Capital | Downgrade | Sector Perform | — |
| 7 Oct 2026 | BTIG | Reiterates | Buy | — |
| 18 Sept 2026 | William Blair | Initiates | Outperform | — |
| 15 Sept 2026 | Wedbush | Reiterates | Outperform | — |
| 19 Aug 2026 | BMO Capital | Initiates | Outperform | — |
| 14 Aug 2026 | B of A Securities | Maintains | Neutral | — |
| 11 Aug 2026 | Piper Sandler | Maintains | Overweight | — |
| 5 May 2026 | BTIG | Reiterates | Buy | — |
| 5 May 2026 | Wedbush | Reiterates | Outperform | — |
| 20 Apr 2026 | Wedbush | Reiterates | Outperform | — |
| 23 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Mar 2026 | B. Riley Securities | Maintains | Buy | — |
| 18 Mar 2026 | UBS | Maintains | Buy | — |
| 18 Mar 2026 | Wedbush | Reiterates | Outperform | — |
| 17 Mar 2026 | BTIG | Reiterates | Buy | — |
| 17 Mar 2026 | RBC Capital | Maintains | Outperform | — |
| 19 Feb 2026 | Piper Sandler | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CATX.
This page is one stock. Monday covers all of them.
CATX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CATX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Perspective Therapeutics, Inc. returned −64.4% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CATX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 413.8×
- Price / book
- 0.3×
- EV / EBITDA
- —
Cheaper than 1% of US stocks
Cheaper than 92% of US stocks
- Revenue growth (YoY)
- −90.4%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
Higher than 2% of US stocks
- Return on equity
- −45.9%
- Return on assets
- −24.9%
- Dividend yield
- —
Higher than 23% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Perspective Therapeutics, Inc. has a market value of $90.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$116.4M.
Free cash flow in the twelve months to 30 June 2026: −$121.2M.
Perspective Therapeutics, Inc. employs 163 people.
Data provided by Twelve Data
CATX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CATX’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Perspective Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CATX
What is the CATX stock price forecast for 2026-2027?
The median 12-month analyst price target for Perspective Therapeutics, Inc. is $9.5, with estimates ranging from $1 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CATX stock a buy right now?
Of the 16 analysts covering Perspective Therapeutics, Inc., 14 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Perspective Therapeutics, Inc. 11 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CATX?
As at 21 Nov 2026, Perspective Therapeutics, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (54 of 100).
Will CATX stock go up?
No one can know that. What the data says: the median 12-month target from 16 analysts is $9.5, and Ticker Nerd's factor model ranks Perspective Therapeutics, Inc. 11 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CATX stock forecast for 2030?
No analyst covering Perspective Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CATX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $15 over the next 12 months.
How has CATX stock performed over the past year?
Perspective Therapeutics, Inc. returned -64.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Perspective Therapeutics, Inc. do?
Perspective Therapeutics Inc. is a radiopharmaceutical company focused on developing and commercializing precision targeted alpha therapies for cancer. The company’s current portfolio centers on treatments and companion imaging agents designed to deliver radiation directly to tumors while helping physicians visualize disease and tailor care.
About Perspective Therapeutics, Inc.
Perspective Therapeutics Inc. is a radiopharmaceutical company focused on developing and commercializing precision targeted alpha therapies for cancer. The company’s current portfolio centers on treatments and companion imaging agents designed to deliver radiation directly to tumors while helping physicians visualize disease and tailor care. Its programs are built around proprietary lead-212-based technology and a theranostic approach that combines diagnosis and treatment in a single oncology platform. Perspective Therapeutics is active in several cancer areas, including neuroendocrine tumors, metastatic melanoma, and other solid tumors, through its clinical-stage development efforts. The company also works on complementary tools and manufacturing capabilities that support its radiopharmaceutical pipeline and clinical operations. Based in Seattle, Perspective Therapeutics plays a specialized role in the broader oncology market by advancing targeted nuclear medicine approaches for cancer care.
CEO Mr. Johan M. Spoor · 163 employees · United States · https://www.perspectivetherapeutics.com